...
首页> 外文期刊>International Journal of Clinical and Experimental Pathology >Significance of multidrug resistance gene-related proteins in the postoperative chemotherapy of gastric cancer
【24h】

Significance of multidrug resistance gene-related proteins in the postoperative chemotherapy of gastric cancer

机译:多药耐药基因相关蛋白在胃癌术后化疗中的意义

获取原文
           

摘要

Background: Multidrug resistance (MDR) is a serious problem in chemotherapy and is one of the main reasons for a poor outcome of gastric cancer. Study on the key proteins in multidrug resistance is necessary for the treatment of gastric cancer. Methods: The expression of ToPo II, MRP and GST-π in 119 gastric cancers was retrospectively examined, and the results were analyzed in correlation with clinicopathological data. ToPo II negative, MRP positive and GST-π positive were regarded as three risk factors which may be associated with chemotherapy resistance and poor prognosis. Patients were divided into two groups: high-risk group (≥2 risk factors) and the low-risk group (<2 risk factors), and the tumor recurrence and patients’ survival time of the two groups were also analyzed. Results: The positive rates of ToPo II, MRP and GST-π were 73.9%, 42.9% and 51.3%, respectively. The positively correlation between the expression of MRP and GST-π had been found. A significant correlation was shown between ToPo II expression and the level of differentiation. Significant differences with GST-π expression were also found in relation to the sex and differentiation. In the high-risk group, the 3-year survival rate of patients with/without chemotherapy were 62.1% and 52.0%, 5-year survival rates were 44.8% and 40.0%, but the difference was not statistically significant (P>0.05). In the low-risk group, the 3-year survival rate of patients with/without chemotherapy were 81.2% and 51.5%, 5-year survival rates were 71.9% and 45.5%, and the difference was statistically significant (P<0.05). Conclusions: Combined detection of MDR-related proteins ToPo II, MRP and GST-π may be prospectively valuable for postoperative individualized chemotherapy, and further predict the outcomes of gastric cancer patients.
机译:背景:多药耐药性(MDR)是化疗中的一个严重问题,并且是导致胃癌预后不良的主要原因之一。研究多药耐药性中的关键蛋白对于治疗胃癌是必要的。方法:回顾性分析119例胃癌中ToPo II,MRP和GST-π的表达,并与临床病理资料进行分析。 ToPo II阴性,MRP阳性和GST-π阳性被认为是可能与化疗耐药和预后不良相关的三个危险因素。将患者分为两组:高危组(≥2个危险因素)和低危组(<2个危险因素),并分析了两组的肿瘤复发和患者的生存时间。结果:ToPo II,MRP和GST-π的阳性率分别为73.9%,42.9%和51.3%。发现MRP的表达与GST-π呈正相关。在ToPo II表达和分化水平之间显示出显着的相关性。还发现与性别和分化有关的GST-π表达有显着差异。高危组中,有/无化疗患者的3年生存率分别为62.1%和52.0%,5年生存率分别为44.8%和40.0%,但差异无统计学意义(P> 0.05)。 。在低危组中,有/无化疗患者的3年生存率分别为81.2%和51.5%,5年生存率分别为71.9%和45.5%,差异有统计学意义(P <0.05)。结论:MDR相关蛋白ToPo II,MRP和GST-π的联合检测对于术后个体化化疗可能具有潜在的价值,并可以进一步预测胃癌患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号